Drug intelligence / Profile preview

BHV-1510 + cemiplimab

Development stage: Unknown
Lead developer: Biohaven
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BHV-1510 + cemiplimab is an investigational combination therapy for advanced or metastatic epithelial and solid tumors, currently in Phase 1/2 clinical trials. BHV-1510 is a next-generation antibody-drug conjugate (ADC) targeting Trop-2, featuring a site-specific conjugation and irreversible linker chemistry, conjugated to a topoisomerase 1 inhibitor payload. Cemiplimab (Libtayo) is a fully human monoclonal antibody and immune checkpoint inhibitor targeting PD-1, approved for multiple advanced malignancies. The combination aims to leverage the cytotoxic and immunogenic effects of BHV-1510 with immune activation provided by cemiplimab, showing synergistic preclinical activity and potential for improved efficacy and safety in high unmet need cancers[1][3][5][7].

Other names: BHV-1510 + LibtayoBHV-1510 + cemiplimab-rwlc

Targets

TACSTD2 (Tumor-associated calcium signal transducer 2)TOP1 (DNA Topoisomerase I)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on BHV-1510 + cemiplimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BHV-1510 + cemiplimab.

Explore the full profile